Daily Archives: January 17, 2021

SOMERVILLE, Mass. (WBZ NewsRadio) The city of Somerville is taking a big step forward towards decriminalizing psychedelic plants and mushrooms.

The city council voted unanimously, nine to zero, on the resolution that makes enforcing laws against psychedelics a low priority.

Councilor Ben Ewen-Campen of Ward Three is a co-sponsor and says there's so much more potential for medical benefits and so much waste of city resources fighting it.

"This is an issue where I just think there is such an enormous gulf between where the science is, where the research is on these substances, honestly where I think public opinion is and where our public policy is," said Ewen-Campen.

READ MORE: A New Law In Quincy Would Ban Airbnb And Other Short-Term Rentals

He adds he believes there are therapeutic potentials for so many of these natural compounds.

Under the resolution, the city's policy states the arrest of people using or possessing psychedelics must be among the lowest law enforcement priority.

The city council is also calling on the Middlesex County District Attorney to stop psychedelic prosecutions.

Councilor J.T. Scott who also co-sponsored it says the resolution sees to it that no city agency or resources be used in helping enforce laws against the use or possession of psychedelic plants.

The resolution does not however allow the commercial sale of psychedelics nor the possession or distribution near schools.

WBZ NewsRadio's James Rojas (@JamesRojasWBZ) reports

Follow this link:

Somerville Taking Steps To Decriminalize Psychedelic Plants And Mushrooms - KFI AM 640

THE UFC are potentially considering using mind-bending psychedelic drugs for the treatment of traumatic brain injuries.

Mushrooms and LSD are just two of the beloved hippie drugs that could end up being used by sufferers of CTE (Chronic Traumatic Encephalopathy).

4

4

Several studies into the potential benefits of CTE and PTSD sufferers using the whacky drugs have been commissioned across the globe.

And the UFC, who recently announced the continuation of their partnership with the Cleveland Clinic and its Professional Athletes Brain Health Study, are now looking to get on board.

The promotion's president, Dana White, told MMA Junkie: "We're diving into that."

The UFC's interest in the study stemmed from a recent HBO 'Real Sports' documentary, which showed former fighters and professional athletes using mushrooms to help heal PTSD and the effects of brain trauma.

FANCY A PUNT? CLAIM 40 IN FREE BETS BY BETTING 10

4

One of those fighters is former UFC flyweight title challenger Ian McCall, who has already held talks with the promotion about the benefits of such drugs.

He said: "When you go into a cage, when you go into a ring and you fight and even football, you're giving and receiving [post-traumatic stress syndrome] and no one wants to talk about it, but that's what's happening.

"Your trauma is stored in your tissue, so you're actually giving and receiving PTSD while you're in there and that's a big reason why I work in psychedelics, to try and fix those exact things.

"We need to take care of these athletes a little better, just like we need to do with vets."

4

DIAZ DISSNate Diaz brands Khabib a 'p***y' after White reveals champ is open to UFC return

DREAM FIGHT JUST THATKhabib fight with Georges St-Pierre 'over' as Russian not interested

MAC IS BACKUFC 257 - McGregor vs Poirier: UK start time, live stream, TV channel, prelims

MAX POWERMax Holloway staying on Fight Island in case Poirier pulls out of McGregor fight

Video

MAD MAXWatch Holloway throw stunning NO-LOOK PUNCH while talking to commentators mid-fight

Latest

KHOMEBACKKhabib opens door to McGregor rematch & will reconsider retirement after UFC 257

Johns Hopkins University is just one of many institutions around the world to recently commission studies into the effects of psychedelics on long-time sufferers of CTE.

The UFC's interest in the American university's study comes following the news that former lightweight standout Spencer Fisher is dealing with the devastating effects of the degenerative disease.

The 44-year-old has been left 'permanently disabled and unable to work' due to his poor cognitive function and is now dependent on the help of his family and medication to get through each day.

Fisher told MMA Fighting: I forget where Im going, depression, dizzy spells, calling people different names, not knowing their actual names.

"My kids, Ive had instances where I couldnt think of their names on the spot. My balance is shot.

"I have a hard time remembering what I did yesterday. Last week is a complete blur.

View original post here:

UFC considering using psychedelic drugs like LSD and mushrooms as controversial therapy for fighters - The Sun

With so many new IPOs and companies launching in the psychedelic industry it's important to fully evaluate the major factors of success or failure in the industry. There are various steps that companies take to have a drug approved and to successfully complete them it takes years and tens of millions of dollars. The further ahead a company moves in the approval process, the more valuable the company becomes, and that is why there is so much excitement for Compass Pathways (CMPS) . Institutional and retail investors are in a frenzy to get a position. The company is in Phase 2b and has received a "Breakthrough Therapy" designation from the FDA, meaning that their therapy has the potential to be more effective than available medications.

Currently there are only a handful of companies that have:

It's important for investors to be mindful of the stage a company is in and to fully evaluate if a company they are investing in has the potential to be successful.

The only companies that have Phase 2 clinical trials now are Compass Pathways, Mind Medicine (MMEDF) , Cybin Inc. (CLXPF) , and Mydecine Innovations Group (MYCOF) . Here's an analysis of these biotech players and we highlight the most undervalued company in the industry.

What is the Drug Discovery Process?

The drug development process being undertaken is to ensure these treatments are safe and effective for consumption.

Psychedelic Companies with Phase 2 Trials Valuation Comparison

Biotechnology companies are hard to value as it's hard to predict success of clinical trials. Biotech companies are unique types of investments that can either pay off handsomely or end with a complete loss of capital. One of the best ways to value a company is by looking at the size of the addressable market and estimating the potential market penetration.

The reason Compass Pathways is leading the charge in psychedelics is they have a drug that is more effective than anything available, has a total addressable market of 16 million adults, and can upend this entire market as a whole.

What key parameters to look for valuing biotech companies?

COMPASS Pathwaysoperates as a mental health care company in the UK and the U.S. It develops COMP360, a psilocybin formulation, which is in Phase IIb clinical trial to treat patients with treatment-resistant depression. The company is currently the most valuable and most well-known company in the industry and has raised over $250 million since its inception.

Current Market Cap: $1.57 Billion

Drug in development: COMP360 Psilocybin for Depression

Indication: Treatment Resistant Depression

Total Addressable Market: $1.12 billion by 2024

Stage: Phase 2B

Location: Multiple sites globally

Mind Medicine, also known as MindMed, is a neuro-pharmaceutical company that discovers, develops and deploys psychedelic inspired medicines to improve health, promote wellness and alleviate suffering. The company's immediate priority is to address the opioid crisis by developing a non-hallucinogenic version of the psychedelic ibogaine. In addition, the company has established a microdosing division to conduct clinical trials of LSD microdosing for adult ADHD. The company has also added MDMA to its R&D pipeline to explore MDMA's potential to treat mental health disorders.

Current Market Cap: $977 Million

Drugs in development: LSD for Adult ADHD, LSD for Suicide Headaches, Ibogaine for Addiction

Indication: Various

Total Addressable Market: Unknown but the largest of all studied companies

Stage: Phase 2a

Location: Multiple sites globally

Cybin is a life sciences company advancing psychedelic pharmaceutical treatments for various psychiatric and neurological conditions. Cybin is developing technologies and delivery systems, aiming to improve bioavailability, to potentially achieve the desired medicinal effects of psychedelics at low dosage levels. The new delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.

Current Market Cap: $203 Million

Drug in development: Sublingual Psilocybin Delivery Mechanism for Depression

Indication: Major Depressive Disorder

Total Addressable Market: $5.8 billion by 2025

Stage: Phase 2 A

Location: University of West Indies Jamaica

Mydecine Innovations Group is a life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing well-being. The company's world-renowned medical and scientific advisory board is progressing a robust R&D pipeline of psychedelic derived therapeutics, novel compounds, therapies, and controlled drug delivery systems. Mydecine has exclusive access to a full cGMP certified pharmaceutical manufacturing facility with the ability to import/export, extract, and analyze natural and synthetic psychedelic compounds with full government approval through Health Canada.

Mydecine was the first company to offer CGMP naturally sourced psilocybin and recently made history again by making the first legal export of Magic Mushrooms. Mydecine has a big focus on intellectual property and is utilizing genome technology (editing plants like what GW Pharma did in Cannabis) under the leadership of Rob Roscow the ex-Canopy Growth (CGC) head of genetics and at Mydecine's U.S. and Canadian laboratories. The company now has over 20 kilos of psilocybin mushrooms - most in the industry - and has active ingredients for their trials at a fraction of the cost that Compass Pathways or Cybin ever can with their synthetic drugs.

Current Market Cap: $56 Million

Drug in development: Naturally Sourced Psilocybin

Indication: PTSD

Total Addressable Market: $10.6 B by 2026

Stage: Phase 2 A

Location: Multiple Sites Globally

As illustrated above, by making side by side comparisons of companies that are in Phase 2 trial studies, investors can quickly see the size of the addressable audience and the market cap of the company. This makes it easier to see if there is a stock that might have more room for upside than others. As the focus on psychedelic stocks increases, so do the valuations. There is concern that some company valuations have gotten ahead of themselves and investors may want to take that into consideration before hitting the buy button.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Link:

As the Focus on Psychedelic Stocks Increases, So Do the Valuations - RealMoney

New research suggests that psychedelics may be a viable treatment option for those suffering from race-based trauma. An observational study, published in Drugs: Education, Prevention & Policy, found that psychedelic experiences were linked to reduced anxiety, depression, and PTSD symptoms among sufferers of racial trauma.

Race-based trauma can be described as trauma resulting from harmful experiences of racism and discrimination which may include physical and verbal assaults. Studies suggest that racial trauma is common among black, indigenous, and people of color (BIPOC), and that even subtle forms of color-blind ideology can provoke lasting mental health consequences. This experience of trauma is linked to heightened anxiety and depression and can lead to post-traumatic stress disorder (PTSD). Study authors Monnica Williams and her team point out that the issue is especially concerning since the BIPOC community faces systemic difficulties when accessing mental health care.

Although several studies have shown that existing treatments may be effective for reducing PTSD symptoms among BIPOC, the development of treatments for racial trauma are sorely lacking, Williams and her colleagues say, highlighting that the effects of psychedelics have been gravely underexplored among people of color.

In the first study of its kind, the researchers investigated whether classic psychedelics might assist the healing of BIPOC suffering from racial trauma.

The researchers recruited a sample of 313 BIPOC who had taken a dose of either psilocybin, LSD, or MDMA and indicated that it had provided relief from the challenging effects of ethnic discrimination. The sample had an average age of 33 and respondents resided in either Canada or the United States.

Respondents answered a series of questions about their experiences with racial or ethnic discrimination across a variety of settings (e.g., community, employment, healthcare). They also answered questions about a single memorable experience with a psychedelic drug, reporting any mystical-type experiences or challenges associated with the substance use. Finally, they reported symptoms of trauma, anxiety, and depression both before and after the psychedelic experience.

When analyzing the data, the researchers observed an overall decrease in trauma symptoms, depressive symptoms, and anxiety symptoms following the psychedelic experience.

It also appeared that the intensity of the psychedelic experience was important. The data showed that those who reported the most intense acute psychedelic effects also reported the greatest reduction in psychological symptoms. In particular, the intensity of the mystical-type experiences was robustly linked to improved symptoms, which falls in line with research suggesting that mystical-type experiences are beneficial to mental health.

The researchers say that challenging experiences (e.g., sadness, isolation, fears of death) associated with psychedelic use appeared to be detrimental to respondents psychological symptoms, suggesting that psychedelic therapists should take care to guide patients through the process in attempt to reduce these negative experiences. In terms of unique challenges faced by BIPOC, the authors note, it would also be important for therapists and guides to have training in culturally-informed approaches and/or be ethnically matched with clients, which would necessitate the training of more diverse psychedelic-assisted therapists (Williams et al., 2019).

Two prominent limitations of the study were that it relied on participant recall which may lead to inaccurate reports and that the sample of respondents was selected to include only those who had reported positive benefits associated with psychedelic experiences. The authors stress that their findings should not be interpreted to mean that psychedelic experiences would be beneficial for all BIPOC dealing with raced-based trauma.

Still, the findings offer a possible avenue of healing for those dealing with racial trauma. As long as discrimination exists, there will be a need for effective treatments to help people suffering from racial trauma, Williams and her colleagues emphasize. The next important step in this work is to conduct clinical trials to determine if the results of this investigation would be replicated in a controlled setting.

The study, People of color in North America report improvements in racial trauma and mental health symptoms following psychedelic experiences, was authored by Monnica T. Williams, Alan K. Davis, Yitong Xin, Nathan D. Sepeda, Pamela Coln Grigas, Sinead Sinnott, and Angela M. Haeny.

More:

Study suggests psychedelics may improve the mental health symptoms of individuals suffering from race-base ... - PsyPost

This article by Dr. James Cookewas originally published onReality Sandwich, and appears here with permission.

The relationship between psychedelics and Judaism is far from simple.Speculation abounds regarding psychoactive substances in theHebrew Bible,yet there is no consensus on the truth of the matter.Many Jewish thinkers have had a huge influence on psychedelic thought. Yet, many have also rejected their Judaism in their approach.Today, however, a strong Jewish strand is emerging on the psychedelics scene.From reviving directreligious experienceto healing intergenerational trauma, psychedelics and Judaism have a lot to offer each other.

Madison Margolin is a journalist who has written extensively on the links between psychedelics and Judaism. She sees psychedelics as having a profound impact on contemporary Judaism. I think psychedelics are invigorating Judaism, theyre reinvigorating our connection to Judaism. Theyre kindling a type of fire that we havent had in a long time. Whats happening is that people are returning to Jewish practice after having been psychedelically inspired and are making it work for them. Psychedelic consciousness is coming together with a hunger for ritual and soulful nourishment and meaning in ones lifewhich Judaism can provideand in this way were really seeing a new, psychedelically inspired Jewish movement.

Judaism is founded on powerful visionary experience, from Moses vision of the burning bush to the divine encounters documented in the Book of Prophets. Is it possible that psychedelics played a role in Jewish religious experience from the very beginning?

The Hebrew Bible opens with the story of Adam and Eve eating the forbidden fruit. It is a divine substance, conferring knowledge on those who eat it.So it isnt far-fetched to imagine that this fruit might represent a naturally occurring psychedelic substance. If this were the case, however, the moral of the story would appear to be to avoid such substances, rather than to consume them.But In Exodus, the Israelites find a divine food called manna growing on the ground.It has been argued that manna may have been a psychoactive fungus, possibly ergot, of whichLSDis a derivative.The main problem with this idea is that the Biblical story does not describe manna as being psychoactive.

In the same book of the Hebrew Bible, Moses has his vision of the burning bush. He puts the tablets with the Ten Commandments on them in the ark of the covenant, a vessel made of acacia wood.Acacia containsDMT, a fact which led psychologist Benny Shanon to speculate that the ancient Israelites may have known how to prepare their own version of the DMT-containing psychedelic brew,ayahuasca.

There is no real evidence for any of these claims of psychoactive drug use in the Hebrew Bible.What is supported by hard evidence, however, is the idea thatcannabiswas used as incense.Archeochemical evidence of burnt cannabis was found along with frankincense on the altar of a shrine at Tel Arad, near Jerusalem. This is where the kingdom of Judah would have been long ago.Cannabis may have been used for more than incense, however.In Exodus, God tells Moses to make a holy anointing oil from kaneh-bosm, a plant whose name translates as fragrant hemp.While many scholars argue that kaneh-bosm is the plant calamus (Acorus calamus, or Sweet Flag), this archeochemical evidence provides evidence that this holy plant may actually have been cannabis.

Psychedelics are known to produce mystical experiences, states in which one discovers oneself to be part of a greater sacred reality. However, it is of course possible to achieve direct religious experience without the use of psychedelics.Kabbalahrepresentsa mystical strand in Judaism which emphasizes such experiences.As a tradition, it contains teachings and practices for engaging with mystical states ofconsciousness.A core text of Kabbalah is the Zohar, a 13th-century text that emerged from mystical traditions in Spain and southern France.The books of the Zohar offer commentaries on the mystical aspects of the Torah, as well as discussions on the nature of God and reality.The work was published by the Sephardic writer Moses de Len of modern-day Spain, then the Kingdom of Len. However, he attributed it to Shimon bar Yochai, a 2nd-century sage from Judea.

As the Sephardic mystical tradition of Kabbalah spread, it influenced the origins of a new mystical strand among the Ashkenazi Jews of eastern Europe: Hasidism.The Hasidic tradition started in the 18th century with Israel Ben Eliezer, a mystic and healer who was also known as theBaal Shem Tov.This spiritual revival movement began in what is now Western Ukraine. Its adherents have preserved many aspects of the culture that founded the moment. These include particular forms of dress and the use of the Yiddish language.As is common in other mystical traditions, Hasidism teaches the imminence of God in the universe, as well as knowing of ones own unity with God.This stands in contrast to nonmystical teachings, in which God is something separate from its creation, a God to stand in relation torather than to discover ones unity with.

Over the last several centuries, European Jewish communities faced dramatic persecution.This ranged from theInquisition in Spain and Portugal, to the pogroms of eastern Europe and the Holocaust.There is no way of knowing the extent of the impact these horrific tragedies have had on these traditions of mystical wisdom.By the 1960s, the Jewish Canadian poet-turned-musician Leonard Cohen bemoaned the loss of this mystical brilliance. He proclaimed, Judaism is a secretion with which an eastern tribe surrounded a divine irritation, a direct confrontation with the absolute. That happened once in history and we still feel the warmth of that confrontation, divorced as we are from the terms of it. That happened a long time ago Today we cannot face heaven, we have lost our genius for the vertical we turn towards ourselves.We knock on our own doors and wonder when no one answers.

At the same time, one method for kindling direct religious experience was filtering through the underground in the West: LSD.

The cultural turbulence of the 1960s resulted in a form of religious revival in the West.LSD provided countless people with instances of direct religious experiences. Many Westerners turned to the East to make sense of these experiences.Some of the most prominent and influential figures in this moment were Jewish.Richard Alpert was one such figure. Raised Jewish, Alpert would go on to conduct research on psilocybin and LSD at Harvard withTimothy Leary.

Alpert traveled in India, looking for a way to integrate his spiritual insights from his psychedelic experimentation. While there, he found his guru, Neem Karoli Baba.Also known as Maharaj Ji to his followers, he gave Alpert the Hindu nameRam Dass, meaning Gods servant.Ram Dass would go on to explore Buddhist mindfulness practices with another influential Jewish contemporary of his, themeditationteacher Joseph Goldstein.Eventually, in his later years he would reckon with the Judaism of his youth.

Ram Dass initially attempted to find religious models for psychedelic experience in religions other than his own.Huge numbers of Jewish Americans in the 1960s and 70s traveled this journey. They were searching for what they hadnt found in the Jewish tradition in which they were raised.According to Madison Margolin, [A] lot of this has to do with Jewish trauma. Especially in the post Holocaust time, people just wanted to assimilate, and there was a lot of internalized antisemitism. If you were coming from a conservadox Jewish background, the type of Judaism you were getting at that point in America was really dry, boring and not spiritual (at least thats how my parents described it).

That in and of itself kind of validates all this Jewish trauma: first it didnt feel safe to be Jewish, and then it didnt feel cool or soulfully nourishing to be Jewish. So that inspired a lot of Jews to go to India or look into spiritual modalities they didnt grow up with. A lot of that was inspired by psychedelics. People were tripping and having these mystical insights, and then not really having the container for integration. I think whats happening now, in this psychedelic renaissance. is theres also a Jewish movement happening. People are having these insights through psychedelics and then theyre going to Jewish religion and inquiring how they can make sense of the psychedelic ethos through a Jewish lens. There are tons of people who are practicing that right now.

Another contemporary of Ram Dass was Rabbi Zalman Schachter-Shalomi.He was the father of the Jewish Renewal movement, which aimed to bring mysticism, ecstatic prayer, and meditation back into Jewish practice.In 1962, Shalomi underwent LSD sessions with Alpert and Leary, sessions that would have a profound impact on him.He was not shy about communicating the value of the psychedelic experience. Accordingly, Shalomi would go on to have a profound influence on modern Jewish spirituality.His trip to India to meet with the Dalai Lama is documented in Rodger Kamenetzsbook,The Jew in the Lotus.The documentary of the same name also tells this story.

In 1976, a man known as Ka-Tzetnik 135633 (original name: Yehiel De-Nur) underwent LSD-assisted psychotherapy. At the time, he was under the supervision of Prof. Jan Bastiaans at the State University of Leiden in the Netherlands.Bastiaans was the psychiatrist who had first identified concentration camp syndrome, also known as survivor syndrome.This syndrome is a form of what we would now call post-traumatic stress disorder (PTSD). Its characteristics include social withdrawal, sleep disturbance, anxiety, and depression.Bastiaans had also successfully treated this syndrome with LSD-assisted psychotherapy.Ka-Tzetnik 135633 was a survivor of Auschwitz, where he was a prisoner for two years.This trauma was followed by three decades of torment, in which he relived the horror of those two years at night.Through LSD-assisted psychotherapy, however, Ka-Tzetnik 135633 found healing.

Almost a half century after Bastiaans successful trials, the regulation of psychedelics for treating PTSD is finally underway. Think of the Holocaust survivors who might have found healing through these medicines, but couldnt because of a politically-motivated ban on psychedelics. This realization brings home the horrific impact of the failed war on drugs.

Two decades after psychedelic research ended in America, Dr. Rick Strassman conducted a trial that examined the effects of DMT on human participants.Raised Jewish, Dr. Strassman had spent his adult life studying Zen Buddhism alongside his medical research career. An understanding of the unitive spiritual state of enlightenment, however, did not prepare him for the effects of DMT. The participants and I were both expecting unitive mystical enlightenment experiences. But only one volunteer had that kind of experience out of almost five dozen. recalls Strassman.

Strassmans participants did not find themselves becoming one with the universe. Rather, they related to and interacted with seemingly autonomous entities in an apparently different realm. Remarkably, this other realm seemed more real than everyday reality.Strassman felt that the Zen perspective couldnt accommodate these experiences, so he returned to Judaism for an explanatory framework.

I went back to the drawing board and by a number of circumstances, I found myself reading the Hebrew Bible.The paradigmatic experience of the Hebrew Bible is the prophetic experience, which, broadly defined, includes any spiritual experience that any figure in the text undergoes. The text posits that the ultimate spiritual experience in the Bible is an interactive relational one.So it matches those two very important criteria: the sense that it is real, the most real thing one might ever meet up with; and the encounter with God or with Gods angels, which is the apogee of Biblical Judaism.

In studying the Hebrew Bible, Strassman found that the visionary experiences of prophets like Ezekiel, Daniel, and Jeremiah showed striking similarities to the DMT-induced state.In addition to the interactive-relational quality, the phenomenology is comparabletheyre both highly visual and emotional. With DMT you feel faint, feeling like youre flying through the air, shaking tremors, anxiety, a rush. There are auditory as well as well as visual effects. The DMT state is intensely color-saturated, rapidly moving, morphing, characterized by visual phenomena. Daniels got rivers of flowing fire. Ezekiels got these beings with wings and there are a lot of eyes on the wings. Jeremiah faints, people see angels, they move through space, and the emotions can be quite powerful; theres fear and trembling.

In both of the states youre confronted with something extremely powerful.Theres an increased feeling of passivity, being overwhelmed. But you can still interact, which is a hallmark of both statesones individual personality is maintained.

Strassman learned biblical Hebrew so that he could translate the challenging text himself. Then he synthesised his psychiatric and scriptural research into an approach he calls theoneurology. I developed that as a counterpoint to the reigning model of spiritual experience from a neuroscientific point of view, which is called neurotheology. Neurotheology is basically your brain on drugs. There are a number of stimulimeditation, prayer, and psychedelicswhich stimulate a brain reflex. [This] manifests in a certain subjective syndrome, and is then after the fact called spiritual. The idea is the brain is so designed in order to provide an evolutionary advantage. For example, you might be more altruistic or compassionate. Its a bottom-up kind of model.

After reading the Hebrew Bible I saw that that isnt the way that that prophecy is understood. Prophecy is understood as a top-down model. God is communicating with humans. So, I developed a top-down model, which I call theoneurology. It puts the preeminence on the spiritual, the divine. And in that model, you would propose that God designed the brain in order for us to be able to communicate with God. So that expands the reason for the brain being designed that way, which is useful because a lot of the prophetic message doesnt make any sense from an evolutionarily advantageous lens.

Strassman continues to work on his translation of the Hebrew Bible.The original text lacks vowels and punctuation, making scholarly commentary and interpretation highly valuable. He is currently working on a translation of Genesis. Understandably, such a translation from a pioneer in the field of psychedelic research would be a huge boon in the area of psychedelics and Judaism.Strassman is also keen to emphasize that a Jewish model of psychedelic spirituality need not be based in mystical traditions like Kabbalah. It isnt essential; it isnt really necessary, I think. [T]he most valuable application isnt to experience a Jewish mystical state. I think whats more important is to revitalize the message of the prophets, the message of the text, and to learn the ethical laws which are embedded in the narratives. That isnt a part of Kabbalah mystical experience.

And theres plenty of mystical experience out there. There doesnt need to be a Jewish flavor. The Hebrew Bible is a unique book with a unique story. It has a unique power, resilience, and applicability. Its the basis of Western civilization. Kabbalah is not the basis of Western civilization. If you really want to make an impact on society, I think it behooves us to go into the lions den. What is motivating a lot of the behavior and beliefs in our world now, its stuff that has been extracted and perverted from the Hebrew Bible. If we can enter into that world with a psychedelic perspective, I think it would be a very powerful tool to turn the power of the Hebrew Bible toward a more beneficial outcome.

The effects of trauma are not confined to individuals who suffer traumatic events. The trauma can be passed down the generations.Moreover, this does not occur only through the emotional impact on child development of having traumatized parents or grandparents. Recent research has shown that trauma can even change theepigeneticregulation of how our DNA is expressed, so that it passes on the post-traumatic stress for three generations.MDMA-assisted psychotherapy is one area that holds great hope for the healing of PTSD.

Rick Doblin is another Jewish psychedelic pioneer who has been essential to the revival of psychedelic medicine.Doblin is the Founder and Executive Director of the Multidisciplinary Association for Psychedelic Studies (MAPS).Thanks to the work of MAPS, MDMA-assisted psychotherapy will soon be available for those suffering from PTSD in the coming years.

The ongoing conflict in the Middle East is one area where many are hoping psychedelic medicine may play a role.While psychological treatment for trauma is no replacement for material change and lasting peace, psychedelics show great promise in reducing human suffering.Israel has already successfully trialed MDMA treatment for PTSD. Additionally, many ayahuasca circles exist in the region.

In 2016, Israeli psychedelic researcher Leor Roseman teamed up with Palestinian peace activist Antwan Saca and Natalie Ginsberg of MAPS to research this phenomenon.In order to explore whether psychedelics might be used to promote peace and reconciliation, they conducted interviews of Israelis and Palestinians who were drinking ayahuasca together.They found that the majority of the individuals they interviewed were taking psychedelics for personal, rather than political, reasons.Despite this, many found that the psychedelic experience cut through the differences of the conflict to their shared humanity.Psychedelics alone are obviously not the answer, however.In an ongoing conflict, many cant come out of their trauma into a position of safety.As one Palestinian interviewee put it, How can you heal trauma if the trauma is ongoing?

A useful resource for those looking to heal from the trauma faced by Jewish communities isTranscendingJewishTrauma.com.This website offers a map of the challenges one can face in response to trauma, as well as guides on the approaches to healing that are available. Another important presence in this area is the nonprofitDarkhei Rephua, which advocates the psychedelic plant medicine path for healing trauma in Jewish communities.The Facebook groupJews for the Therapeutic Use of Psychedelicsis a great place to start for those interested in this area.More general access points for those looking to explore psychedelics in a Jewish context include theJewish Psychedelic SocietyandJewish Entheogenic SocietyFacebook groups.

Another key figure in the area of psychedelics and Judaism is Adriana Kertzer. She is a Jewish Brazilian-American lawyer whose law firm,Plant Medicine Law Group, focuses on the psychedelic and cannabis space. As a side project, she leads the working group Faith+Delics, a group of Jews and Christians exploring the potential incorporation of psychedelics into these traditions. I started exploring the relationship between Jews and drugs through my Instagram accountJewWhoTokes, explains Kertzer, who derives the most pleasure from acting as a connector in the space. [W]hat began as a joke is now a deep passion. What are the different ways in which Jewish identity and psychedelics overlap? What does a Jewish psychedelic philanthropic ecosystem look like?

In addition to healing, advocates of psychedelics are harnessing their capacity to invoke religious experience in order to bring the mystical experience back into Jewish religious practice.Rabbi Zac Kamenetz took part in a research study in which religious practitioners were given a dose ofpsilocybin.His experiences have led him to see psychedelics as a valuable tool for Jewish spirituality.His nonprofit, Shefa, is dedicated to integrating psychedelics into Jewish religious practice.

We know that the medicalization, therapeutic application, or decriminalization of psychedelics will not be the end of the story. With the potential to grant access to encounters with the Sacred, religious traditions must prepare themselvesfrom their theologies to their liturgies and communal structuresto enrich and be enriched by more access to psychedelic medicine and sacrament.

While we are still several years out from being able to use these plants and compounds outside of a clinical setting, we launched Shefa now because we understand how much work must go into preparing for a psychedelically-integrated Judaism in terms of research, education, and building a network of Jewish guides that are well-traveled in expanded states as they are captured in our mystical traditions and in their own lives. We hope our work will inspire other religious leaders and traditions to walk this path with us as well.

Read the original Article on Reality Sandwich.

Benzinga's Related Links:

2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

More:

Psychedelics And Judaism: A History Of Jewish Mysticism - Benzinga

The strategic partnership between Mind Cure and ATMA will bridge access to research locations for psychedelic drug research while providing patient data for iSTRYM, Mind Cure's digital therapeutics platform.

VANCOUVER, BC, Jan. 12, 2021 /PRNewswire/ -Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("Mind Cure" or the "Company") is pleased to announce the signing of a non-binding letter of intent (the "LOI") for strategic investment and commercial cooperation with ATMA Journey Centers Inc. ("ATMA"), aCalgary-based organization. ATMA is the first commercial treatment center in Canada to announce providing psychedelic-assisted therapy for a section 56 exempt patient. The LOI is intended to help Mind Cure secure an equity position within ATMA, empowering the Company with access to a global release strategy for iSTRYM,as well as international locations for translational research on novel molecules and treatment protocols.

"ATMA's clinicians possess a proven track record of advocacy and innovation driving toward the therapeutic benefits of psychedelic medicine for patients in the treatment of mental health and wellness. Mind Cure is extremely excited to join ATMA in the renaissance that is disrupting mental health care by partnering with one of the pioneers in the therapeutic psychedelics industry," said Kelsey Ramsden, President & CEO, Mind Cure. "With Mind Cure's therapeutic tool, iSTRYM, along with ATMA's pivotal achievement as the care provider for Canada's most recent section 56(1) exempt patient, mental health care in Canada is making history. We are thrilled to work with the best-in-class to drive our focus on accelerating our research and technology platforms."

Mind Cure's partnership with ATMA is an exciting opportunity for researchers and therapists to participate in each of Mind Cure's research programs focused on pain, neuroregeneration, migraines, and cluster headaches. The proposed investment will facilitate the syndication of Mind Cure's psychedelic drug protocols and the use of Mind Cure's proprietary technology, iSTRYM, to optimize treatment for ATMA clients.

The deployment of capital will also advance speed and scale for data enrichment of iSTRYM, providing the AI-driven platform with access to patient data as ATMA targets domestic and international healing and treatment centers.

"Psilocybin-assisted therapy offers healing and understanding that is unmatched by traditional methods. Patients dealing with end-of-life anxiety, pain, depression, trauma, and addiction have been at the mercy of ineffective and underwhelming treatments for much too long. The resources are here, and we are extremely grateful to be at the frontlines of this world-changing, innovative, and extremely alleviating solution, to help bring peace to sufferers," said David Harder, co-CEO, ATMA Journey Centers Inc. "We are witnessing an inflection point for mental health treatment as the commitment to wellness in Canada takes a huge step forward."

Pursuant to the LOI, the parties intend to negotiate the terms of definitive agreements (the "Definitive Agreements"), which will provide for, among other things an initial $500,000 investment by Mind Cure in ATMA, participation by Mind Cure in ATMA's future financings, and the exclusive use of iSTRYM throughout ATMA's business. There can be no assurance that the Definitive Agreements will be entered into or that the investment or commercial transactions will be completed on the terms proposed in the LOI or at all.

About ATMA Journey Centers Inc. and SYNTAC Institute

ATMA is a private healthcare company with the mission of delivering effective and innovative healing and transformative experiences that awaken the inner healer and promote a deeper connection with the self, with others, and with the beauty of the world. ATMA is the first private sector service provider in Canada to announce psychedelic-assisted therapy provision under the approval of Health Canada's Section 56(1) exemption, which will allow ATMA to provide psilocybin-assisted therapy to those seeking psychedelic assisted therapy.

ATMA's founding members, David Harder, Greg Habstritt, and Vu Tran, also founded SYNTAC Institute, a non-profit organization with the mission of bringing the healing and transformative power of psychedelic medicine and psychedelic-assisted therapy to Canadians. SYNTAC has been an influential participant in the Canadian psychedelic medicine industry and operates Catalyst Presents, a series of conferences and summits in Canada focused on psychedelics.

About Mind Cure Health Inc.

Mind Cure exists as a response to the current mental health crisis and urgent calls for effective treatments. Mind Cure believes in the need to reinvent the mental health care model for patients and practitioners to allow psychedelics to advance into common and accepted care.

Mind Cure is focused on identifying and developing pathways and products that ease suffering, increase productivity, and enhance mental health. Mind Cure is interested in exploring diverse therapeutic areas beyond psychiatry, including digital therapeutics, neuro-supports, and psychedelics, all to improve mental health.

On Behalf of the Board of Directors Kelsey Ramsden, President & CEO Phone: 1-888-593-8995

Forward-Looking Information

Certain statements in this news release may constitute "forward-looking information" within the meaning of applicable securities laws (also known as forward-looking statements). Forward-looking information involves known and unknown risks, uncertainties and other factors, and may cause actual results, performance or achievements or industry results, to be materially different from any future results, performance or achievements or industry results expressed or implied by such forward-looking information. Forward-looking information generally can be identified by the use of terms and phrases such as "anticipate", "believe", "could", "estimate", "expect", "feel", "intend", "may", "plan", "predict", "project", "subject to", "will", "would", and similar terms and phrases, including references to assumptions. Some of the specific forward-looking information in this news release includes, but is not limited to, statements with respect to: the conclusion of the transactions and negotiation of the Definitive Agreements contemplated by the LOI on the terms disclosed herein, or at all; ATMA conducting additional psychedelic-assisted therapy; the disruption of mental health care through psychedelic-based therapies; the development of iSTRYM and incorporation into ATMA's business; the relationship with ATMA accelerating the development of Mind Cure's research and technology platforms; participation of researchers and therapists in Mind Cure's research programs; Mind Cure's investment facilitating the syndication of Mind Cure's psychedelic drug protocols and the development of those protocols; protocols and iSTRYM to optimize treatment for ATMA clients and driving greater access to patient data for the AI-driven digital therapeutics platform; the roll-out of domestic and international treatment centres by ATMA; the realization of an inflexion point for mental health treatment; and Mind Cure's collection of data from ATMA's section 56 exempt clients.

Forward-looking information is based on a number of key expectations and assumptions made by Mind Cure, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and Mind Cure's business, and the extent and duration of such impact; no change to laws or regulations that negatively affect Mind Cure's business; there will be a demand for Mind Cure's products and ATMA's clinics in the future; no unanticipated expenses or costs arise; Mind Cure will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; the partnership with ATMA will help Mind Cure achieve its business goals; and Mind Cure will be able to operate its business as planned. Although the forward-looking information contained in this news release is based upon what Mind Cure believes to be reasonable assumptions, it cannot assure investors that actual results will be consistent with such information.

Forward-looking information is provided for the purpose of presenting information about management's current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Those risks and uncertainties include, among other things, risks related to: the impacts of the COVID-19 pandemic on the Canadian economy, Mind Cure's industry and Mind Cure's business, which may negatively impact, and may continue to negatively impact, Mind Cure and may materially adversely affect Mind Cure's investments, results of operations, financial condition, and Mind Cure's ability to obtain additional equity or debt financing, and satisfy its financial obligations; general economic conditions; future growth potential; competition for mental health and wellness investments; Mind Cure's partnership with ATMA may not help Mind Cure achieve its business goals; iSTRYM, and its database function may not be successfully developed or help to optimize protocols and enhance scientific research; and changes in legislation or regulations. Management believes that the expectations reflected in the forward-looking information contained herein are based upon reasonable assumptions and information currently available; however, management can give no assurance that actual results will be consistent with such forward-looking information. Additional information on the risk factors that could affect Mind Cure can be found under "Risk Factors" in Mind Cure's final prospectus which is available on SEDAR at http://www.sedar.com.

The forward-looking information contained herein is expressly qualified in its entirety by this cautionary statement. Forward-looking information reflects management's current beliefs and is based on information currently available to Mind Cure. The forward-looking information is stated as of the date of this news release and Mind Cure assumes no obligation to update or revise such information to reflect new events or circumstances, except as may be required by applicable law.

The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.

SOURCE Mind Cure Health Inc.

Read more:

Mind Cure Signs LOI to Acquire an Ownership Interest in Psychedelic Treatment Center ATMA, Selected by Section 56 Exempt Patient for Psilocybin...

LONDON & NEW YORK--(BUSINESS WIRE)--Eleusis Ltd, a clinical-stage life science company dedicated to unlocking the full therapeutic potential of psychedelics, today announced that it has appointed David E. Nichols, Ph.D., a renowned expert on the pharmacology and medicinal chemistry of psychedelics, as its Director of Molecular Pharmacology. He will collaborate closely with his son, Charles Nichols, Ph.D., the scientific founder of Eleusis, in an effort to accelerate the transformation of psychedelics into medicines.

Dr. David Nichols is an Adjunct Professor at the University of North Carolina Chapel Hill, where he continues research. Prior to his retirement, he served as Distinguished Professor of Medicinal Chemistry and Molecular Pharmacology, and as the Robert C. and Charlotte P. Anderson Distinguished Chair in Pharmacology at Purdue University. He is the founding president of the Heffter Research Institute, which was instrumental in the clinical reemergence of psychedelics, supporting early research into psilocybin at UCLA, Johns Hopkins, NYU, and other leading universities.

We share Dr. Nichols deep commitment to unlocking the full therapeutic potential of psychedelics, within psychiatry and beyond psychiatry, said Shlomi Raz, CEO of Eleusis. Davids expertise and experience are unmatched, and we are thrilled to have him lead our molecular pharmacology and medicinal chemistry program.

I have studied the chemistry and pharmacology of psychedelics since 1969 and am convinced that psychedelics possess an incredible therapeutic potential if thoughtfully developed, said Dr. Nichols. The tremendous strides Eleusis and my son, Charles, have made over the past few years give me confidence that the company is on the verge of realizing this potential, and I am delighted to be joining the team.

Eleusis is developing psychedelic infusion therapies intended to enhance the therapeutic profile of ketamine and psilocybin. Two of the companys leading therapeutic candidates, ELE-Ket+ and ELE-Psilo+, are expected to enter Phase II clinical trials for the adjunctive treatment of major depressive disorder at the end of 2021. Eleusis pipeline also includes preclinical and clinical-stage assets that harness the profound anti-inflammatory and neuroprotective potential of psychedelics devoid of perceptual effects.

I have been fascinated by the profound anti-inflammatory properties of psychedelics ever since I discovered them and am thrilled to now work together with my father to realize their potential, said Dr. Charles Nichols. I am confident we will transform psychedelics into new and powerful anti-inflammatory medicines.

About Eleusis Ltd.

Founded in 2013, Eleusis is the first privately held, clinical-stage life science company dedicated to unlocking the full therapeutic potential of psychedelics, guided by science, and enabled by drug discovery, clinical development, and care delivery design. The companys comprehensive discovery, development, and delivery capabilities enable it to target a broad spectrum of unmet needs within psychiatry, and beyond psychiatry. For more information, visit https://www.eleusisltd.com/.

Read this article:

Eleusis Accelerates Psychedelic Drug Discovery and Development Team with Appointment of David Nichols, Ph.D., as Director of Molecular Pharmacology -...

Researchers have started to explore the potential for psilocybin, the psychedelic drug found in "magic" mushrooms, to treat obesity.

Already, a mounting body of research from scientists at Johns Hopkins and New York University suggests the drug can help with anxiety and depression when traditional antidepressant medications don't work.

That's because psychedelics like psilocybin have the ability to change how information moves through the brain, decreasing negative thoughts, self-criticisms, and overwhelming feelings. A mindset change can positively affect a person's overall life outlook and how they move about the world every day.

Now, Dr. C. Laird Birmingham, an eating disorder specialist and epidemiologist, is working with psychedelics research startup NeonMind to design a study that examines whether the trippy drug could be effective for weight-loss purposes.

Read more: 'Magic' mushrooms could treat long-term depression 4 times better than anti-depressants, study finds

The study, which will take place at the University of British Columbia, is still in its design phase, but Birmingham said previous psilocybin research suggests it's promising.

"Psilocybin has the potential to serve as a new and different tool to help people lose weight and maintain their weight loss by changing neural pathways," Birmingham said in a press release emailed to Insider. Those neural changes could teach the brain to stop linking "life stress and trauma to eating behavior," he said.

In some cases, obesity can be attributed to overeating, especially in the US where it's considered an epidemic.

Certain diseases like polycystic ovarian syndrome and Cushing's disease may also contribute to weight gain, and antidepressant medications and food insecurity have also been shown to contribute. In those cases, using psychedelic drugs to create a mindset change wouldn't get to the root of the issue.

But the drug could potentially help with all kinds of behavior- and addiction-related maladies, including overeating and under-eating, according to Matthew Johnson, a Johns Hopkins researcher who has published various studies on psilocybin 's mental-health benefits.

His team is in the process of completing their own study on how psilocybin could help people with anorexia nervosa, an eating disorder that affects about 328,200 adults in the US.

Read more: A Navy SEAL veteran with PTSD said a 'magic' mushroom trip put an end to his depression

"There's a very good case to be made that the long-term effects that we see with psychedelics are more akin to the long term effects we see from psychotherapy," Johnson told Insider.

He said that people who have had psilocybin trips in clinical settings appear to learn something from those experiences, which change their thinking for the long-term, much like therapy can.

Of course, psilocybin isn't the perfect answer. A subset of the population could respond poorly to psychedelics if they have a history of psychotic disorders, and a bad trip that dissuades a user from ever trying the drug again is a possibility, said Johnson.

That's why he only advocates for clinical trials, which require in-depth pre-screenings and follow-up sessions.

Continue reading here:

Researchers believe 'magic' mushrooms have the potential to curb obesity - Insider - INSIDER

Acquisition of industry-leading instrument by Thermo Fisher Scientific will significantly advance psychedelic research and accelerate third-party standardized testing capabilities

VANCOUVER, BC, Jan. 13, 2021 /CNW/ -Numinus Wellness Inc.("Numinus" or the "Company") (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), is excited to announce it has acquired theOrbitrap Exploris 120 mass spectrometer with Vanquish Flex Binary("Orbitrap") instrument for its continued research and development of Psilocybe mushroom related projects at Numinus Bioscience, the Company's 7,000 square foot analytics and research laboratory.

Implementation of the Orbitrap, a state-of-the-art high resolution mass spectrometry instrument, will continue the accelerated trajectory of Numinus Bioscience's research strategy to optimize cultivation, harvest, and extraction of Psilocybe mushrooms. This follows Numinus' successful completion of the first legal extraction in Canada by a public company for research and development purposes in December.

"Numinus continues to break ground in the research and development of psychedelic-assisted psychotherapies, and the implementation of the Orbitrap Exploris 120 mass spectrometer with Vanquish Flex Binary cements our role as the centre of excellence for psychedelic research and development," said Sharan Sidhu, Science Officer and General Manager, Numinus. "As an early psychedelic substances license holder, this announcement demonstrates our commitment to staying at the forefront of psychedelic initiatives. Acquiring the Orbitrap is a fundamental step forward in developing Numinus Bioscience's first patent, significantly advancing Psilocybe Mushroom related psychedelic discovery research and accelerating our third-party psychedelic standardized testing capabilities."

Numinus Bioscience is focused on developing analytical methods and formulations for the evolving psychedelics space by establishing itself at the forefront of analytical testing for psychedelics. Use of the Orbitrap Exploris 120 will allow Numinus to accelerate psychedelic standardized testing, research and development activities for third-party clients and strategic partners, as well as high throughput testing for amenable compounds.

As well, the Orbitrap will be instrumental in ensuring that dried Psilocybe Mushrooms provided for special access are safe and that the therapeutic compounds consistently meet all required specifications. This follows Health Canada's groundbreaking announcement of its intention to revise the Special Access Programme (SAP) to permit access to MDMA and psilocybin-assisted psychotherapy in the same way other investigational medications are accessed in Canada.

Health Canada's Notice of Intent regarding the SAP will be open for public consultation and comments for the next 60 days, and Numinus strongly encourages the community to weigh in on the benefits of the revision. View the notice here:http://www.gazette.gc.ca/rp-pr/p1/2020/2020-12-12/html/notice-avis-eng.html#nb2.

To share comments and thoughts related to the SAP, please email [emailprotected]a.

About Psychedelic-Assisted Psychotherapy

Psychedelic-assisted psychotherapy has gained a great deal of interest within the medical community and general public asresearch results demonstrate its superior effectiveness for a range of mental health conditions. These results are contributing to a paradigm shift in both the understanding and treatment of mental health conditions.

Numinus has announced plans to embark upon open-label compassionate access clinical trials ofpsilocybin-assisted psychotherapy for substance use disorders andMDMA-assisted psychotherapy for PTSD, enabling it to implement, test and refine optimal protocols for delivery before these therapies are widely accessible. This includes developing physical and human resource infrastructure more broadly to deliver psychedelic-assisted psychotherapy including for Special Access Programme patients.

Numinus is uniquely positioned to provide patients with MDMA and psilocybin-assisted psychotherapy under the expanded SAP revision based on its international partnerships and extensive work completed on developing safe and evidence-based protocols for psychedelic-assisted psychotherapy. The Company is also a leader in the industry as the first public entity in Canada to receive a licence to produce and extract psilocybin from mushrooms, the first to complete a legal harvest and extraction of Psilocybe mushrooms using this licence and the holder of a Health Canada dealer's licence to import, export, possess, test and distribute MDMA, psilocybin and other psychedelics.

Applications for Numinus's compassionate access trials and for access under the SAP, pending approval, are not yet open. To be advised of the status and procedures for applications when available,register for Numinus's newsletter.

About Numinus

Numinus Wellness Inc.(TSXV: NUMI) is a mental health and wellness company creating an ecosystem of solutions centred around safe, evidence-based, accessible psychedelic-assisted psychotherapy to help people heal and be well.

Numinus Healthis dedicated to delivering innovative treatments to address physical, mental, and emotional health, through clinics and virtual services.

Numinus R&Dis conducting implementation science and leveraging partnerships to beta-test and refine optimal models of psychedelic-assisted psychotherapy delivery, setting the stage for approved routine use in mental health and wellness care.

Numinus Bioscienceis focused on developing testing methods and effective formulas for the evolving psychedelics space. Health Canada licences, scientific expertise, and new technologies facilitate ongoing innovation, and high-throughput contract services generate established revenue.

Learn more at numinus.ca, and follow us on Facebook, Twitter, and Instagram.

Forward Looking Statements

This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are "forward-looking statements." Forward-looking statements can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward looking statements. Such risks and uncertainties include, among others, dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing federal, provincial, municipal, local or other licences and any inability to obtain all necessary governmental approvals licences and permits to operate and expand the Company's facilities; regulatory or political change such as changes in applicable laws and regulations, including federal and provincial legalization, due to inconsistent public opinion, perception of the medical-use and adult-use marijuana industry, bureaucratic delays or inefficiencies or any other reasons; any other factors or developments which may hinder market growth; the Company's limited operating history and lack of historical profits; reliance on management; the Company's requirements for additional financing, and the effect of capital market conditions and other factors on capital availability; competition, including from more established or better financed competitors; and the need to secure and maintain corporate alliances and partnerships, including with research and development institutions, customers and suppliers. These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company has no obligation to update any forward-looking statement, even if new information becomes available as a result of future events, new information or for any other reason except as required by law.

SOURCE Numinus Wellness Inc.

For further information: Dana Harvey, Chief Communications Officer, Numinus Wellness Inc, [emailprotected]

https://numinus.ca/

Read the original here:

Numinus Wellness Forges Forward into Psychedelic Discovery Research with the Orbitrap Exploris 120 Mass Spectometer - Canada NewsWire